Tempus AI (NASDAQ:TEM) Research Coverage Started at Robert W. Baird

Robert W. Baird began coverage on shares of Tempus AI (NASDAQ:TEM) in a research note issued to investors on Tuesday, Marketbeat reports. The firm issued an outperform rating and a $59.00 price target on the stock.

A number of other research firms also recently issued reports on TEM. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. HC Wainwright reduced their target price on Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a report on Friday, November 7th. TD Cowen lowered Tempus AI from a “buy” rating to a “hold” rating in a research report on Tuesday, October 21st. Canaccord Genuity Group lowered their target price on Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, December 22nd. Finally, Morgan Stanley upped their price target on Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Eight equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $85.92.

Tempus AI Stock Up 6.8%

Shares of Tempus AI stock opened at $59.96 on Tuesday. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. Tempus AI has a 12-month low of $36.22 and a 12-month high of $104.32. The company has a market cap of $10.67 billion, a P/E ratio of -50.39 and a beta of 5.22. The company’s fifty day simple moving average is $62.60 and its two-hundred day simple moving average is $73.38.

Insiders Place Their Bets

In related news, CFO James William Rogers sold 19,966 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the sale, the chief financial officer directly owned 111,250 shares of the company’s stock, valued at $8,143,500. This trade represents a 15.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $63.99, for a total value of $10,638,337.50. Following the completion of the sale, the chief executive officer owned 8,974,783 shares of the company’s stock, valued at $574,296,364.17. The trade was a 1.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 544,188 shares of company stock worth $37,163,496 in the last three months. Corporate insiders own 26.27% of the company’s stock.

Institutional Trading of Tempus AI

A number of large investors have recently made changes to their positions in TEM. Invesco Ltd. lifted its position in Tempus AI by 21.5% during the fourth quarter. Invesco Ltd. now owns 371,674 shares of the company’s stock valued at $21,947,000 after purchasing an additional 65,836 shares during the period. Vident Advisory LLC grew its position in Tempus AI by 5.3% in the 4th quarter. Vident Advisory LLC now owns 10,376 shares of the company’s stock worth $613,000 after purchasing an additional 522 shares during the period. Oracle Investment Management Inc. bought a new stake in Tempus AI in the 4th quarter worth approximately $384,000. EP Wealth Advisors LLC purchased a new stake in Tempus AI during the 4th quarter valued at $553,000. Finally, Regal Partners Ltd bought a new position in shares of Tempus AI during the 4th quarter valued at $531,000. 24.22% of the stock is currently owned by institutional investors.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus announced a new pan‑cancer HRD‑RNA algorithm for homologous recombination deficiency detection — a clinical/ product milestone that investors see as expanding Tempus’s diagnostic addressable market and commercialization runway. Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm
• Positive Sentiment: Market headlines note the stock rise after the algorithm launch, framing the update as momentum into earnings — a near‑term sentiment catalyst. Tempus AI stock rises after launching new cancer detection algorithm
• Positive Sentiment: Coverage (247WallSt/Yahoo syndication) highlights the algorithm as the reason shares are climbing and points to the upcoming Q4 report as the next major catalyst. Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings
• Positive Sentiment: Yahoo Finance and other outlets explain the same narrative: product news + pre‑earnings positioning has lifted sentiment — but note they also list items investors should watch before earnings. Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings
• Positive Sentiment: General consumer/press Q&A pieces summarize the move and point investors to upcoming earnings and product commercialization as the primary drivers. What’s going on with Tempus AI stock today?
• Neutral Sentiment: Zacks digs into Wall Street estimates for Q4 key metrics, offering deeper model inputs investors can use to set expectations for the Feb. 24 report. Unlocking Q4 Potential of Tempus (TEM): Exploring Wall Street Estimates for Key Metrics
• Neutral Sentiment: Another Zacks piece weighs TEM’s expected ~82.8% revenue growth vs. premium valuation — useful context but highlights the tradeoff between growth and valuation risk into earnings. Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
• Neutral Sentiment: Forbes examines the valuation question at ~$60 — notes TEM trades at a premium on traditional metrics and remains GAAP‑unprofitable, but discusses why growth/analyst optimism may still justify interest. Is TEM Stock A Buy At $60?
• Neutral Sentiment: Robert W. Baird initiated coverage with an “outperform” and $59 PT — the initiation adds legitimacy but the price target is roughly in line with current levels, signaling limited near‑term upside per that call. Baird initiation article
• Neutral Sentiment: Analysis pieces reassessing valuation after recent weakness highlight the gap between analyst targets and market price; these are reminders that downside exists if growth disappoints. Assessing Tempus AI (TEM) Valuation After Recent Share Price Weakness And Analyst Target Gap
• Neutral Sentiment: Market roundup pieces include TEM in broader market context; useful for macro risk but not company‑specific news. Stock Market Live February 17, 2026

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.